Fuji Pharma Co.,Ltd. Logo

Fuji Pharma Co.,Ltd.

Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.

4554 | T

Overview

Corporate Details

ISIN(s):
JP3816200004
LEI:
Country:
Japan
Address:
千代田区三番町5番地7
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products for medical use. The company specializes in hormone medicines, particularly for obstetrics and gynecology, and injectable drugs. Its portfolio also includes internal drugs, external use medications, and diagnostic products. In addition to its proprietary products, Fuji Pharma offers a wide range of contract manufacturing services for various formulations, including solids, injections, ointments, creams, and liquids. The company is noted for its extensive experience and specialized quality containment technology in the production of hormone-based pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-09 04:10
Registration Form
確認書
Japanese 8.7 KB
2025-05-09 04:09
Interim Report
半期報告書-第61期(2024/10/01-2025/09/30)
Japanese 216.6 KB
2024-12-23 04:46
Post-Annual General Meeting Information
臨時報告書
Japanese 25.0 KB
2024-12-23 04:37
Registration Form
確認書
Japanese 8.7 KB
2024-12-23 04:33
Governance Information
内部統制報告書-第60期(2023/10/01-2024/09/30)
Japanese 23.3 KB
2024-12-23 04:32
Registration Form
有価証券報告書-第60期(2023/10/01-2024/09/30)
Japanese 1.7 MB
2024-07-18 09:11
Registration Form
有価証券届出書(参照方式)
Japanese 285.7 KB
2024-05-10 07:27
Quarterly Report
四半期報告書-第60期第2四半期(2024/01/01-2024/03/31)
Japanese 216.0 KB
2024-05-10 07:27
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-09 08:20
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-09 08:19
Quarterly Report
四半期報告書-第60期第1四半期(2023/10/01-2023/12/31)
Japanese 178.7 KB
2023-12-21 07:28
Post-Annual General Meeting Information
臨時報告書
Japanese 27.9 KB
2023-12-21 07:26
Registration Form
確認書
Japanese 8.7 KB
2023-12-21 07:25
Governance Information
内部統制報告書-第59期(2022/10/01-2023/09/30)
Japanese 23.3 KB
2023-12-21 07:23
Annual Report
有価証券報告書-第59期(2022/10/01-2023/09/30)
Japanese 1.6 MB

Automate Your Workflow. Get a real-time feed of all Fuji Pharma Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuji Pharma Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuji Pharma Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.